Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
International Immunopharmacology|April 20, 2016
Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancerArio Takeuchi, Masatoshi Eto, Katsunori Tatsugami, et al.
Urologic Oncology|September 9, 2020
The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?Kosuke Ieiri, Masaki Shiota, Eiji Kashiwagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor ImmunityTokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, et al.
Cancer Science|October 16, 2020
Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expressionMasaki Shiota, Yohei Sekino, Shigehiro Tsukahara, et al.
Oncotarget|August 11, 2018
Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockadeKentaro Tanaka, Toyoshi Yanagihara, Yuki Ikematsu, et al.
Anticancer Research|July 20, 2021
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective AnalysisTakashi Morisaki, Takafumi Morisaki, Makoto Kubo, et al.
Scientific Reports|September 15, 2017
Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cellsKevin J Tam, Daniel H F Hui, Wilson W Lee, et al.
Japanese Journal of Clinical Oncology|January 22, 2021
External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohortKeita Tamura, Takahiro Osawa, Ario Takeuchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 30, 2023
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart reviewJunji Yonese, Nobuyuki Hinata, Satoru Masui, et al.
EMBO Molecular Medicine|January 20, 2018
SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1James W Peacock, Ario Takeuchi, Norihiro Hayashi, et al.
Pageof 12